PATENT CLAIM ANALYSIS

Application Number: 16308457
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-09
Patent Classification: ["514", "234200"]

Abstract:
A crystalline modification of triazolopyrazine derivatives binds to a hepatocyte growth factor (HGF) to activate phosphorylation, thereby significantly inhibiting the activity of c-Met kinase triggering cell proliferation, migration, and formation of new blood vessels. Therefore, the compound of the present application may be effectively used for the treatment or prevention of various hyper proliferative disorders mediated by hyper proliferation activation of cells and excessive angiogenesis.

Claim (Index 30):
A method of preparing the crystalline modification type VII of  claim 19 , the method comprising:\n (a) dissolving or dispersing 30 to 70 mg of a crystalline modification type I compound of Chemical Formula 1 in 0.5 to 2 mL of water; (b) stirring a dispersion produced in step (a) at 15 to 28\u00b0 C. for 1 to 24 hours; and (c) recovering a material precipitated in step (b) by filtration and drying the recovered material at 15 to 28\u00b0 C.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 98.0
- Lexical Diversity: 1.2807
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13141142', '13143831', '14609137', '14158182', '13728350']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7375940736532373
- 35 USC 102 Novelty (BERT): 0.5315546914397812
- Combined Prediction Score: 0.7169901354318917
- Mean Citation Score: 301.166224
- Max Citation Score: 334.4524
- Similarity Product: 229.079421638155

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test